Brad Briggs is the Editorial Director of StreetAuthority. A veteran of the financial publishing industry, Brad manages the team of writers and editors responsible for our premium newsletters, free newsletters, and website. He formerly co-wrote our Maximum Profit premium newsletter, and is also the managing editor for StreetAuthority's premium subscribers-only newsletter, StreetAuthority Insider.
Brad bought his first stock in high school and has been hooked ever since. After graduating early from college, success in the market enabled him to pay off his student loans and buy his first house. Brad believes that successful investing doesn't have to be complicated, and that anyone can achieve financial independence no matter their background. One of his proudest accomplishments is holding on to Apple since 2014.
As Editorial Director, Brad makes it his mission to demystify the world of investing for a wide audience. His writing has been featured in outlets like Yahoo Finance, Nasdaq.com, and MSN Money, among others.
When he's not following the market, Brad spends his time powerlifting and tending to cattle near his home in Texas.
Analyst Articles
It’s amazing what a simple metric can tell you about a company. Especially an unflappably accurate metric. This yardstick cuts to the chase and tells you exactly how well a company performs. It’s in every company’s SEC filings. It’s on nearly… Read More
Wall Street loves to make things hard. People are mystified by the black arts practiced in the world’s financial capitals. These sorcerers hold a secret that everyone from a lowly financial adviser to a big-time deal maker doesn’t want you to know . . . The secret: It’s not hard… Read More
When the financial meltdown began with the collapse of Lehman Brothers, the talking heads on financial news channels pronounced the death of “buy-and-hold” investing. It had become unfashionable. No one was willing to defend the idea of buying a stock and holding on to it for years. I don’t know… Read More
China has had an impressive run. Its GDP has grown at double-digit rates while holders of Chinese stocks have earned triple-digit returns. While everyone else is talking about China, savvy investors should be asking where the next big growth story is. The investment company… Read More
The U.S. isn’t the only country struggling to reform its health-care system. China has a big problem on its hands: 1.3 billion people and a system that has been ignored for decades. The World Health Organization recently ranked China’s health care 144th out of 190 countries. The country recently said… Read More
Benjamin Graham, the father of value investing, once described his strategy as “buying dollars for 50 cents.” He would have loved this market. Graham had several tricks to determine whether a company was undervalued. One of them was assessing its book value, a figure… Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings...
Read More
The Dow recently crossed the 9,000 mark on the back of a solid start to the second-quarter earnings season, while the S&P is up +10% for the year. The market couldn’t have made it to this...
Read More
The largest savings and loan in the United States said second-quarter earnings were up 16% from last year. Net income rose to $127.9 million, or 26 cents a share, compared with $110.7 million, or 22 cents a… Read More
Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More
Healthcare giant Johnson & Johnson (NYSE: JNJ) said this morning that second-quarter earnings amounted to $1.15 a share. The results, a -4.7% decline from a year ago, beat expectations, despite challenges facing the company’s pharmaceutical unit and a stronger dollar. The company said… Read More
